How to buy Adaptive Biotechnologies shares in Ireland | $46.93

Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NYSE and all prices are listed in US Dollars. Adaptive Biotechnologies employs 453 staff and has a trailing 12-month revenue of around USD$92.4 million.

Sponsored For

Beginners Choice

DEGIRO

Sponsored For

Low-cost Trading

eToro

Sponsored For

Overall Broker

Plus500

How to buy shares in Adaptive Biotechnologies from Ireland

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Adaptive Biotechnologies Find the stock by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$46.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade stocks, ETFs and CFDs

Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89 % of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Sort by:

Name	Product	Number of Stocks	CFDs	Shares	Available Markets	Link
DEGIRO		Access to global markets	No	Yes	AU, AT, BE, CA, CH, CZ, DE, DK, ES, FR, FI, GR, HK, HU, IT, JP, NO, PT, PL, IE, SG, SE, TR, UK, US	Go to site More Info	Your capital is at risk.		loading Fetching your data...
eToro		2,000+	Yes	Yes	Worldwide with exception.	Go to site 71% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...
Plus500		2,000+	Yes	Yes	US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK	Go to site 76.4% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

How has coronavirus impacted Adaptive Biotechnologies's share price?

Since the stock market crash in March caused by coronavirus, Adaptive Biotechnologies's share price has had significant positive movement.

Its last market close was USD$46.93, which is 27.21% up on its pre-crash value of USD$34.16 and 208.95% up on the lowest point reached during the March crash when the shares fell as low as USD$15.19.

If you had bought USD$1,000 worth of Adaptive Biotechnologies shares at the start of February 2020, those shares would have been worth USD$755.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,564.18.

Adaptive Biotechnologies share price

Is it a good time to buy Adaptive Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Adaptive Biotechnologies under- or over-valued?

Valuing Adaptive Biotechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adaptive Biotechnologies's P/E ratio

Adaptive Biotechnologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Adaptive Biotechnologies shares trade at around 44x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Shorting Adaptive Biotechnologies shares

There are currently 3.9 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 46.1% down from 7.2 million last month.

There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.

Adaptive Biotechnologies's "short interest ratio" (SIR)

Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 817396.19450317). Adaptive Biotechnologies's SIR currently stands at 4.73. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 4730 shares are currently held short.

However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 30 shares are currently held short) or 0.0569% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 57 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.

Frequently asked questions

• What percentage of Adaptive Biotechnologies is owned by insiders or institutions?

  Currently 5.163% of Adaptive Biotechnologies shares are held by insiders and 78.616% by institutions.

• How many people work for Adaptive Biotechnologies?

  Latest data suggests 453 work at Adaptive Biotechnologies.

• When does the fiscal year end for Adaptive Biotechnologies?

  Adaptive Biotechnologies's fiscal year ends in December.

• Where is Adaptive Biotechnologies based?

  Adaptive Biotechnologies's address is: 1551 Eastlake Avenue East, Seattle, WA, United States, 98102

• What is Adaptive Biotechnologies's ISIN number?

  Adaptive Biotechnologies's international securities identification number is: US00650F1093

• What is Adaptive Biotechnologies's CUSIP number?

  Adaptive Biotechnologies's Committee on Uniform Securities Identification Procedures number is: 00650F109